JP2011519574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519574A5 JP2011519574A5 JP2011507987A JP2011507987A JP2011519574A5 JP 2011519574 A5 JP2011519574 A5 JP 2011519574A5 JP 2011507987 A JP2011507987 A JP 2011507987A JP 2011507987 A JP2011507987 A JP 2011507987A JP 2011519574 A5 JP2011519574 A5 JP 2011519574A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tissue
- positive
- cell population
- adult
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 299
- 238000000034 method Methods 0.000 claims description 85
- 210000001519 tissue Anatomy 0.000 claims description 66
- 210000004185 liver Anatomy 0.000 claims description 48
- 210000000130 stem cell Anatomy 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 210000004504 adult stem cell Anatomy 0.000 claims description 30
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 claims description 29
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 23
- 102000008730 Nestin Human genes 0.000 claims description 22
- 108010088225 Nestin Proteins 0.000 claims description 22
- 210000005055 nestin Anatomy 0.000 claims description 22
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 102100032912 CD44 antigen Human genes 0.000 claims description 18
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 18
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 18
- 102100032412 Basigin Human genes 0.000 claims description 17
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims description 17
- 210000003494 hepatocyte Anatomy 0.000 claims description 17
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 15
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 15
- 239000002458 cell surface marker Substances 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 14
- 210000000496 pancreas Anatomy 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 12
- 239000002356 single layer Substances 0.000 claims description 12
- 230000007850 degeneration Effects 0.000 claims description 11
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 10
- 210000000277 pancreatic duct Anatomy 0.000 claims description 9
- 210000000481 breast Anatomy 0.000 claims description 8
- 210000002919 epithelial cell Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000005228 liver tissue Anatomy 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 210000000442 hair follicle cell Anatomy 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 description 68
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
- 230000014509 gene expression Effects 0.000 description 35
- 102000004877 Insulin Human genes 0.000 description 32
- 108090001061 Insulin Proteins 0.000 description 32
- 229940125396 insulin Drugs 0.000 description 32
- 239000002609 medium Substances 0.000 description 24
- 241000700159 Rattus Species 0.000 description 19
- 102100027211 Albumin Human genes 0.000 description 18
- 108010088751 Albumins Proteins 0.000 description 18
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 13
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 13
- 102100038081 Signal transducer CD24 Human genes 0.000 description 13
- 102000013127 Vimentin Human genes 0.000 description 13
- 108010065472 Vimentin Proteins 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 210000005048 vimentin Anatomy 0.000 description 13
- 210000001900 endoderm Anatomy 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 11
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 11
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 11
- -1 c-Met Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 102000051325 Glucagon Human genes 0.000 description 9
- 108060003199 Glucagon Proteins 0.000 description 9
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 9
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 9
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 9
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 9
- 229960004666 glucagon Drugs 0.000 description 9
- 230000004660 morphological change Effects 0.000 description 9
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 8
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 8
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 8
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 7
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 7
- 229940096919 glycogen Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 210000002304 esc Anatomy 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 210000003716 mesoderm Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 4
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 4
- 108010066302 Keratin-19 Proteins 0.000 description 4
- 108010070507 Keratin-7 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 101150052863 THY1 gene Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 3
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 101150003286 gata4 gene Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 2
- 108010042606 Tyrosine transaminase Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- 101100260565 Dictyostelium discoideum thyA gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 102000009094 Hepatocyte Nuclear Factor 3-beta Human genes 0.000 description 1
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101000930457 Rattus norvegicus Albumin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000034149 carbohydrate storage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QVFWZNCVPCJQOP-UHFFFAOYSA-N chloralodol Chemical compound CC(O)(C)CC(C)OC(O)C(Cl)(Cl)Cl QVFWZNCVPCJQOP-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000020619 endoderm development Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000026917 foregut morphogenesis Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 101150068774 thyX gene Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5209808P | 2008-05-09 | 2008-05-09 | |
| US61/052,098 | 2008-05-09 | ||
| PCT/GB2009/001149 WO2009136168A1 (en) | 2008-05-09 | 2009-05-08 | Materials and methods relating to cell based therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519574A JP2011519574A (ja) | 2011-07-14 |
| JP2011519574A5 true JP2011519574A5 (cg-RX-API-DMAC7.html) | 2012-06-21 |
Family
ID=40935531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507987A Pending JP2011519574A (ja) | 2008-05-09 | 2009-05-08 | 細胞ベースの治療に関連する材料および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20110158961A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2283115A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011519574A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102083964B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009136168A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012020308A2 (en) | 2010-08-13 | 2012-02-16 | The University Court Of The University Of Glasgow | Cellular and molecular therapies |
| BR112014031676A2 (pt) | 2012-06-26 | 2017-10-31 | Seraxis Inc | composição, e, métodos para gerar uma composição e para gerar células pancreáticas substitutas |
| WO2014091373A1 (en) | 2012-12-11 | 2014-06-19 | The University Court Of The University Of Glasgow | Cellular and molecular therapies for peripheral vascular disease |
| CA3019514A1 (en) | 2016-03-30 | 2017-10-05 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
| US20190183937A1 (en) * | 2016-08-18 | 2019-06-20 | Sapporo Medical University | Life extension agent |
| CN110546251A (zh) | 2017-04-04 | 2019-12-06 | 小利兰·斯坦福大学托管委员会 | 成体多能干细胞的制备、扩增及应用 |
| WO2019060548A1 (en) * | 2017-09-20 | 2019-03-28 | Mora Sergio | METHOD FOR EXPANSION OF HUMAN PANCREATIC PROGENITOR CELLS FROM STEM CELLS USING MEDIA CONDITIONED BY NOURISHED CELLS |
| CN113646422B (zh) | 2018-09-19 | 2025-03-11 | 谱系细胞疗法股份有限公司 | 用于在动态悬浮培养中分化多能干细胞的方法 |
| EP3852527A4 (en) | 2018-09-21 | 2022-11-02 | Apstem Therapeutics, Inc. | HUMAN MULTIPOTENTED ADULT STEM CELLS |
| SG11202107732XA (en) | 2019-01-23 | 2021-08-30 | Asterias Biotherapeutics Inc | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
| JP2022527277A (ja) * | 2019-03-26 | 2022-06-01 | ザ・ペン・ステイト・リサーチ・ファウンデイション | がんを処置するための方法及び材料 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020012653A1 (en) * | 1997-12-19 | 2002-01-31 | Kevin Pang | Bile duct progenitor cells and methods of use |
| US6878543B1 (en) * | 1999-10-25 | 2005-04-12 | Nsgene Sa | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
| CN100420739C (zh) * | 2001-09-20 | 2008-09-24 | 抗癌公司 | 表达巢蛋白的毛囊干细胞 |
| US20040029269A1 (en) * | 2002-05-07 | 2004-02-12 | Goldman Steven A | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells |
| GB0509748D0 (en) * | 2005-05-13 | 2005-06-22 | Univ Glasgow | Materials and methods relating to cell based therapies |
-
2009
- 2009-05-08 CN CN2009801260075A patent/CN102083964B/zh not_active Expired - Fee Related
- 2009-05-08 JP JP2011507987A patent/JP2011519574A/ja active Pending
- 2009-05-08 EP EP09742364A patent/EP2283115A1/en not_active Withdrawn
- 2009-05-08 US US12/991,878 patent/US20110158961A1/en not_active Abandoned
- 2009-05-08 WO PCT/GB2009/001149 patent/WO2009136168A1/en not_active Ceased
-
2013
- 2013-05-21 US US13/898,625 patent/US20130280219A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519574A5 (cg-RX-API-DMAC7.html) | ||
| JP2011519574A (ja) | 細胞ベースの治療に関連する材料および方法 | |
| CA2867953C (en) | Regulating stem cells | |
| Dabeva et al. | Hepatic stem cells and liver repopulation | |
| JP6000982B2 (ja) | 臍由来細胞を使用する筋萎縮性側索硬化症の治療 | |
| US20100151574A1 (en) | Multipotent progenitor cell derived from adipose tissue | |
| KR20080056302A (ko) | 태반 유래 줄기세포로부터 생산된 희소돌기 아교세포 | |
| JP2005523328A (ja) | 胎盤由来の幹細胞及びその使用 | |
| CN112891374B (zh) | 治疗中风的影响的方法 | |
| JP2008119002A (ja) | 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用 | |
| JP2012512654A (ja) | 馴化培地、および馴化培地を作る方法 | |
| JP6860921B2 (ja) | 血液細胞を用いた組織・臓器の作製方法 | |
| WO2012133948A1 (ja) | 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物 | |
| CN115361960A (zh) | 用于治疗慢性移植物抗宿主病的方法 | |
| JPWO2004101775A1 (ja) | 新規な成体組織由来の幹細胞およびその用途 | |
| Shi et al. | In vitro differentiation of mouse bone marrow mononuclear cells into hepatocyte-like cells | |
| WO2004083414A1 (ja) | 単球由来多能性細胞ｍｏｍｃ | |
| JP2023001294A (ja) | 臓器線維症の予防または治療剤 | |
| JPWO2005024004A1 (ja) | 間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞 | |
| WO2021201286A1 (ja) | ハイポテンシャル多能性幹細胞 | |
| Moshrefi et al. | Transplantation of differentiated umbilical cord mesenchymal cells under kidney capsule for control of type I diabetes in rat | |
| US20110052545A1 (en) | Regeneration system, its production and use | |
| Watanabe et al. | Differentiation of a hepatic phenotype after heterotropic transplantation of heart, kidney, brain, and skin tissues into liver in F344 rats | |
| Rios et al. | Stem cells and their contribution to tissue repair | |
| LOUKOGEORGAKIS et al. | Recent developments in therapies with stem cells from amniotic fluid and placenta |